PH12015502115B1 - Compositions and methods for live, attenuated alphavirus formulations - Google Patents
Compositions and methods for live, attenuated alphavirus formulationsInfo
- Publication number
- PH12015502115B1 PH12015502115B1 PH12015502115A PH12015502115A PH12015502115B1 PH 12015502115 B1 PH12015502115 B1 PH 12015502115B1 PH 12015502115 A PH12015502115 A PH 12015502115A PH 12015502115 A PH12015502115 A PH 12015502115A PH 12015502115 B1 PH12015502115 B1 PH 12015502115B1
- Authority
- PH
- Philippines
- Prior art keywords
- live
- compositions
- attenuated
- methods
- attenuated alphavirus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 230000002238 attenuated effect Effects 0.000 title abstract 7
- 241000710929 Alphavirus Species 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 abstract 2
- 239000007995 HEPES buffer Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784122P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/026570 WO2014151855A1 (en) | 2013-03-14 | 2014-03-13 | Compositions and methods for live, attenuated alphavirus formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015502115A1 PH12015502115A1 (en) | 2016-01-25 |
| PH12015502115B1 true PH12015502115B1 (en) | 2019-08-09 |
Family
ID=50489420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502115A PH12015502115B1 (en) | 2013-03-14 | 2015-09-14 | Compositions and methods for live, attenuated alphavirus formulations |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10137186B2 (enExample) |
| EP (2) | EP3603667A1 (enExample) |
| JP (3) | JP6426695B2 (enExample) |
| KR (1) | KR20160003662A (enExample) |
| CN (2) | CN105377293B (enExample) |
| AP (1) | AP2015008733A0 (enExample) |
| AU (2) | AU2014236804B2 (enExample) |
| BR (1) | BR112015023205A2 (enExample) |
| CA (1) | CA2903711A1 (enExample) |
| CR (1) | CR20150553A (enExample) |
| DO (1) | DOP2015000226A (enExample) |
| EC (1) | ECSP20007842A (enExample) |
| MX (2) | MX361342B (enExample) |
| MY (1) | MY178476A (enExample) |
| NZ (1) | NZ631012A (enExample) |
| PH (1) | PH12015502115B1 (enExample) |
| SG (3) | SG10201909051QA (enExample) |
| TW (2) | TW201900192A (enExample) |
| WO (1) | WO2014151855A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ631012A (en) | 2013-03-14 | 2017-08-25 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| EP3087188A1 (en) | 2013-12-23 | 2016-11-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| PE20190149A1 (es) * | 2016-03-31 | 2019-01-22 | Takeda Vaccines Inc | Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas |
| NL2022538B1 (en) * | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
| KR102890748B1 (ko) * | 2021-01-19 | 2025-11-26 | 니타 젤라틴 가부시키가이샤 | 바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| RU2035508C1 (ru) * | 1991-08-16 | 1995-05-20 | Институт органической химии СО РАН | Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей |
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| WO1996017072A2 (en) * | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6458560B1 (en) * | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
| EP1100944A1 (en) * | 1998-07-30 | 2001-05-23 | The Johns Hopkins University School Of Medicine | Targeted alphavirus and alphaviral vectors |
| US6869907B2 (en) * | 2000-05-02 | 2005-03-22 | Pentax Corporation | Color-image-forming medium |
| FR2814957B1 (fr) * | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
| WO2003049763A1 (en) * | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| AU2003247337B2 (en) | 2002-04-11 | 2007-09-06 | Medimmune, Llc | Preservation of bioactive materials by freeze dried foam |
| WO2005058356A2 (en) | 2003-12-17 | 2005-06-30 | Wyeth | Methods for porducing storage stable viruses and immunogenic compositions thereof |
| WO2008026225A2 (en) | 2006-09-01 | 2008-03-06 | Bharat Biotech International Limited | A vaccine for chikungunya virus infection |
| US20090047255A1 (en) * | 2006-11-03 | 2009-02-19 | Alphavax, Inc. | Alphavirus and Alphavirus Replicon Particle Formulations and Methods |
| RU2541784C2 (ru) | 2006-11-07 | 2015-02-20 | Санофи Пастер Байолоджикс Ко. | Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения |
| CN101679954A (zh) | 2007-04-06 | 2010-03-24 | 伊维拉根公司 | 用于活的减毒病毒的方法和组合物 |
| CN107693787A (zh) | 2007-09-04 | 2018-02-16 | 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) | 轮状病毒的热灭活 |
| KR20160005378A (ko) | 2007-09-14 | 2016-01-14 | 사노피 파스테르 바이오로직스, 엘엘씨 | 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물 |
| JP5758632B2 (ja) | 2008-01-24 | 2015-08-05 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 |
| CA2745096C (en) | 2008-12-09 | 2013-11-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| WO2011090712A2 (en) | 2009-12-28 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
| CN102939104A (zh) | 2010-06-01 | 2013-02-20 | 诺华有限公司 | 用冻干浓缩疫苗抗原 |
| NZ631012A (en) | 2013-03-14 | 2017-08-25 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
-
2014
- 2014-03-13 NZ NZ631012A patent/NZ631012A/en not_active IP Right Cessation
- 2014-03-13 SG SG10201909051Q patent/SG10201909051QA/en unknown
- 2014-03-13 MX MX2015012894A patent/MX361342B/es active IP Right Grant
- 2014-03-13 EP EP19172758.5A patent/EP3603667A1/en not_active Withdrawn
- 2014-03-13 BR BR112015023205A patent/BR112015023205A2/pt not_active IP Right Cessation
- 2014-03-13 KR KR1020157029550A patent/KR20160003662A/ko not_active Ceased
- 2014-03-13 US US14/209,921 patent/US10137186B2/en not_active Expired - Fee Related
- 2014-03-13 MY MYPI2015002316A patent/MY178476A/en unknown
- 2014-03-13 CN CN201480018785.3A patent/CN105377293B/zh not_active Expired - Fee Related
- 2014-03-13 CN CN202010573138.6A patent/CN111729077A/zh active Pending
- 2014-03-13 WO PCT/US2014/026570 patent/WO2014151855A1/en not_active Ceased
- 2014-03-13 JP JP2016502179A patent/JP6426695B2/ja not_active Expired - Fee Related
- 2014-03-13 CA CA2903711A patent/CA2903711A1/en not_active Abandoned
- 2014-03-13 SG SG11201507462QA patent/SG11201507462QA/en unknown
- 2014-03-13 SG SG10201801459SA patent/SG10201801459SA/en unknown
- 2014-03-13 EP EP14717940.2A patent/EP2968515B1/en active Active
- 2014-03-13 AP AP2015008733A patent/AP2015008733A0/xx unknown
- 2014-03-13 AU AU2014236804A patent/AU2014236804B2/en not_active Ceased
- 2014-03-13 TW TW107130863A patent/TW201900192A/zh unknown
- 2014-03-13 TW TW103109097A patent/TWI649087B/zh not_active IP Right Cessation
-
2015
- 2015-09-09 DO DO2015000226A patent/DOP2015000226A/es unknown
- 2015-09-14 PH PH12015502115A patent/PH12015502115B1/en unknown
- 2015-09-14 MX MX2018014977A patent/MX2018014977A/es unknown
- 2015-10-14 CR CR20150553A patent/CR20150553A/es unknown
-
2018
- 2018-10-01 AU AU2018236897A patent/AU2018236897B2/en not_active Ceased
- 2018-10-12 US US16/159,221 patent/US10806781B2/en not_active Expired - Fee Related
- 2018-10-25 JP JP2018200754A patent/JP6761015B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-31 EC ECSENADI20207842A patent/ECSP20007842A/es unknown
- 2020-09-03 JP JP2020148154A patent/JP2020193231A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| CL2016001547A1 (es) | Composiciones para el cuidado oral | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| GB2535876A (en) | Absorbent clumping animal litter compositions | |
| MX2015012737A (es) | Vacunas de virus bovino liquidas estables. | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| MX2016007316A (es) | Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli. | |
| PH12019501722A1 (en) | Compositions and methods for promoting hair growth with mpc1 inhibitors | |
| PH12017500627A1 (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| MX2016012112A (es) | Feromona tranquilizadora para gatos. | |
| MX2019010101A (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
| MX2017014971A (es) | Composiciones de sal mejoradas y metodo de preparacion de las mismas. | |
| PH12018502119A1 (en) | Compositions and methods for stabilizing alphaviruses with improved formulations | |
| EA201591867A1 (ru) | Композиция лютеина, подходящая для составов детского питания | |
| AR095118A1 (es) | Un procedimiento de inactivación viral en composición que comprende factor vii | |
| MX2014015767A (es) | Composiciones de etanol producidas termoquimicamente. | |
| IN2014MU00284A (enExample) | ||
| MX2016001694A (es) | Formulacion de vacuna de sacarido. | |
| NZ708737A (en) | Thrombin solution and methods of use thereof | |
| TH179835A (th) | องค์ประกอบและวิธีการสำหรับสูตรตำรับอัลฟาไวรัสซึ่งถูกทำให้อ่อนฤทธิ์ที่มีชีวิต | |
| MY182603A (en) | An extract of baeckea frutescens and its use in the treatment of gout | |
| UA88646U (uk) | Перфторароматичні ізомерні дифторфенілазометинфенілові етери як мономери для поліетеразометинів |